Citations 2
Multidimensional Single-Cell Transcriptomic Profiling of Uterine Leiomyosarcomas Reveals Distinct Tumor States with Inferred Therapeutic Vulnerabilities
Korah, Maria, Agolia, James Paul , Reddy, Biren , Flojo, Renceh A. B., Wang, Lilin , Bethi, Rishik, Bobst, Wesley, Liang, Brooke, Yip, Kaylin A., Tabora, Angela D, Hsu, Chia-Hsin, Reveron‐Thornton, Rosyli F. , Guo, Chuner, Delitto, Andrea E., Xie, Peter Y., Tomasso, Antonio, Daniel, Sara K. , Litkouhi, Babak , Moding, Everett J. , Poultsides, George A. , Norton, Jeffrey A. , Charville, Gregory W. , Ganjoo, Kristen N. , Lee, Byrne , Longaker, Michael T., Gonçalves, Amanda Costa , Bethi, Rishik, Liang, Brooke, Yip, Kaylin A., Hsu, Chia-Hsin, Guo, Chuner, Gruener, Robert F. , Xie, Peter Y., Tomasso, Antonio, Sun, Beatrice J. , Dorigo, Oliver , Bui, Nam Q. , Pan, Minggui , Kalbasi, Anusha K. , Kirane, Amanda , Newman, Aaron M. , Foster, Deshka S. , Huang, R. Stephanie , Delitto, Daniel
No container title available | November 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Uterine leiomyosarcoma (ULMS) is an orphan disease that frequently recurs and metastasizes, with patients undergoing multiple lines of chemotherapy due to lack of effective therapeutic targets. To address this gap, we used single-cell RNA sequencing and spatial transcriptomic analysis to comprehensively profile ULMS. We uncovered multiple states of tumor cells, including tumor cells with mesenchyme-like features, ischemic tumor cells defined by a MYC program, inflammatory tumor cells with active interferon signaling, and stem cell-like hormone receptor-positive cells. The inferred spatial correlates of these tumor cell states demonstrated unique localization patterns. By correlating these signatures to bulk RNA sequencing data, we demonstrate the relevance of these findings to clinical outcomes. Finally, using the single-cell integration and drug response prediction algorithm (scIDUC), we propose drug predictions that may target specific tumor states. Our findings suggest new avenues for further exploration of individualized and multifaceted therapeutic strategies to treat ULMS.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.
Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.